Pfizer (PFE) Stock Price
Pfizer Price
Over the last 19 years Pfizer grew revenue by 1.4% annually, reaching 62.58 B USD. Earnings per share have declined at 0.6% per year over the last 19 years. For Pfizer, the net margin of 12.4% is down versus 27.2% a few years ago. At today's price the dividend yield works out to roughly 6.42%. The payout ratio is around 126% of earnings. The dividend has grown at 3.1% per year over the past 19 years. The consensus 12-month price target for Pfizer is 28.56 USD, about 6.6% above where the stock trades today. Of 33 analysts, 15 rate the stock a buy — an overall Hold consensus. The stock trades about 14% above its 52-week low.
Pfizer stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Pfizer over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Pfizer stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Pfizer's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Pfizer Price |
|---|---|
| 8/14/2026 | 26.79 USD |
| 8/13/2026 | 26.80 USD |
| 8/12/2026 | 26.31 USD |
| 8/11/2026 | 26.62 USD |
| 8/10/2026 | 27.07 USD |
| 8/7/2026 | 26.76 USD |
| 8/6/2026 | 26.20 USD |
| 8/5/2026 | 25.51 USD |
| 8/4/2026 | 25.61 USD |
| 8/3/2026 | 25.03 USD |
| 7/31/2026 | 25.01 USD |
| 7/30/2026 | 24.91 USD |
| 7/29/2026 | 25.25 USD |
| 7/27/2026 | 24.82 USD |
| 7/23/2026 | 25.01 USD |
| 7/22/2026 | 24.82 USD |
| 7/21/2026 | 24.94 USD |
| 7/20/2026 | 24.75 USD |
| 7/17/2026 | 25.05 USD |
| 7/16/2026 | 25.14 USD |
| 7/15/2026 | 24.82 USD |
| 7/14/2026 | 24.25 USD |
| 7/13/2026 | 24.47 USD |
| 7/10/2026 | 24.17 USD |
| 7/9/2026 | 24.25 USD |
| 7/8/2026 | 24.01 USD |
| 7/7/2026 | 24.07 USD |
| 7/6/2026 | 23.73 USD |
| 7/2/2026 | 24.32 USD |
| 7/1/2026 | 23.88 USD |
| 6/30/2026 | 24.08 USD |
| 6/29/2026 | 24.17 USD |
| 6/26/2026 | 24.29 USD |
| 6/25/2026 | 23.67 USD |
| 6/24/2026 | 24.04 USD |
| 6/23/2026 | 24.72 USD |
| 6/22/2026 | 25.03 USD |
| 6/18/2026 | 25.02 USD |
| 6/17/2026 | 26.18 USD |
| 6/16/2026 | 25.98 USD |
| 6/15/2026 | 26.37 USD |
| 6/12/2026 | 26.39 USD |
| 6/11/2026 | 26.32 USD |
| 6/10/2026 | 25.70 USD |
| 6/9/2026 | 25.70 USD |
| 6/8/2026 | 25.62 USD |
| 6/5/2026 | 26.00 USD |
| 6/4/2026 | 25.75 USD |
| 6/3/2026 | 25.40 USD |
| 6/2/2026 | 25.43 USD |
| 6/1/2026 | 25.50 USD |
| 5/29/2026 | 26.03 USD |
| 5/28/2026 | 26.17 USD |
| 5/27/2026 | 26.42 USD |
| 5/26/2026 | 25.80 USD |
| 5/22/2026 | 25.77 USD |
| 5/21/2026 | 25.81 USD |
| 5/20/2026 | 25.88 USD |
| 5/19/2026 | 25.66 USD |
| 5/18/2026 | 25.33 USD |
| 5/15/2026 | 25.33 USD |
| 5/14/2026 | 25.75 USD |
| 5/13/2026 | 25.96 USD |
| 5/12/2026 | 25.87 USD |
| 5/11/2026 | 25.81 USD |
| 5/8/2026 | 25.68 USD |
| 5/7/2026 | 26.48 USD |
| 5/6/2026 | 26.53 USD |
| 5/5/2026 | 26.45 USD |
| 5/4/2026 | 26.30 USD |
| 5/1/2026 | 26.33 USD |
| 4/30/2026 | 26.70 USD |
| 4/29/2026 | 26.26 USD |
| 4/28/2026 | 26.48 USD |
| 4/27/2026 | 26.79 USD |
| 4/24/2026 | 27.00 USD |
| 4/23/2026 | 26.67 USD |
| 4/22/2026 | 26.80 USD |
| 4/21/2026 | 27.31 USD |
| 4/20/2026 | 27.52 USD |
| 4/17/2026 | 27.56 USD |
| 4/16/2026 | 27.22 USD |
| 4/15/2026 | 27.19 USD |
| 4/14/2026 | 27.11 USD |
| 4/13/2026 | 27.34 USD |
| 4/10/2026 | 26.92 USD |
| 4/9/2026 | 27.22 USD |
| 4/8/2026 | 27.47 USD |
| 4/7/2026 | 27.10 USD |
| 4/6/2026 | 27.83 USD |
| 4/2/2026 | 28.28 USD |
| 4/1/2026 | 28.55 USD |
| 3/31/2026 | 28.08 USD |
| 3/30/2026 | 27.77 USD |
| 3/27/2026 | 27.04 USD |
| 3/26/2026 | 27.57 USD |
| 3/25/2026 | 27.42 USD |
| 3/24/2026 | 27.03 USD |
| 3/23/2026 | 26.82 USD |
| 3/20/2026 | 27.03 USD |
| 3/19/2026 | 27.41 USD |
| 3/18/2026 | 27.41 USD |
| 3/17/2026 | 27.44 USD |
| 3/16/2026 | 26.64 USD |
| 3/13/2026 | 26.65 USD |
| 3/12/2026 | 26.93 USD |
| 3/11/2026 | 27.25 USD |
| 3/10/2026 | 27.04 USD |
| 3/9/2026 | 26.81 USD |
| 3/6/2026 | 26.87 USD |
| 3/5/2026 | 26.61 USD |
| 3/4/2026 | 26.62 USD |
| 3/3/2026 | 26.58 USD |
| 3/2/2026 | 27.26 USD |
| 2/27/2026 | 27.65 USD |
| 2/26/2026 | 27.10 USD |
| 2/25/2026 | 27.09 USD |
| 2/24/2026 | 27.14 USD |
| 2/23/2026 | 27.06 USD |
| 2/20/2026 | 26.64 USD |
| 2/19/2026 | 26.85 USD |
| 2/18/2026 | 27.31 USD |
| 2/17/2026 | 27.39 USD |
| 2/13/2026 | 27.59 USD |
| 2/12/2026 | 27.52 USD |
| 2/11/2026 | 27.71 USD |
| 2/10/2026 | 27.57 USD |
| 2/9/2026 | 27.08 USD |
| 2/6/2026 | 27.13 USD |
| 2/5/2026 | 26.45 USD |
| 2/4/2026 | 26.62 USD |
| 2/3/2026 | 25.83 USD |
| 2/2/2026 | 26.63 USD |
| 1/30/2026 | 26.36 USD |
| 1/29/2026 | 26.11 USD |
| 1/28/2026 | 25.81 USD |
| 1/27/2026 | 26.42 USD |
| 1/26/2026 | 25.76 USD |
| 1/23/2026 | 25.61 USD |
| 1/22/2026 | 26.14 USD |
| 1/21/2026 | 25.86 USD |
| 1/20/2026 | 25.54 USD |
| 1/16/2026 | 25.68 USD |
| 1/15/2026 | 25.82 USD |
| 1/14/2026 | 25.55 USD |
| 1/13/2026 | 25.15 USD |
| 1/12/2026 | 25.29 USD |
| 1/9/2026 | 25.48 USD |
| 1/8/2026 | 25.32 USD |
| 1/7/2026 | 25.25 USD |
| 1/6/2026 | 25.39 USD |
| 1/5/2026 | 25.14 USD |
| 1/2/2026 | 25.20 USD |
| 12/31/2025 | 24.92 USD |
| 12/30/2025 | 25.02 USD |
| 12/29/2025 | 25.04 USD |
| 12/26/2025 | 25.10 USD |
| 12/24/2025 | 25.03 USD |
| 12/23/2025 | 24.92 USD |
| 12/22/2025 | 25.23 USD |
| 12/19/2025 | 25.25 USD |
| 12/18/2025 | 25.07 USD |
| 12/17/2025 | 25.07 USD |
| 12/16/2025 | 25.47 USD |
| 12/15/2025 | 26.39 USD |
| 12/12/2025 | 25.89 USD |
| 12/11/2025 | 25.83 USD |
| 12/10/2025 | 25.79 USD |
| 12/9/2025 | 25.35 USD |
| 12/8/2025 | 25.81 USD |
| 12/5/2025 | 26.01 USD |
| 12/4/2025 | 25.70 USD |
| 12/3/2025 | 25.57 USD |
| 12/2/2025 | 25.17 USD |
| 12/1/2025 | 25.34 USD |
| 11/28/2025 | 25.74 USD |
| 11/26/2025 | 25.72 USD |
| 11/25/2025 | 25.72 USD |
| 11/24/2025 | 25.20 USD |
| 11/21/2025 | 25.10 USD |
| 11/20/2025 | 24.39 USD |
| 11/19/2025 | 24.85 USD |
| 11/18/2025 | 25.42 USD |
| 11/17/2025 | 25.09 USD |
| 11/14/2025 | 25.09 USD |
| 11/13/2025 | 25.79 USD |
| 11/12/2025 | 25.79 USD |
| 11/11/2025 | 25.46 USD |
| 11/10/2025 | 24.40 USD |
| 11/7/2025 | 24.41 USD |
| 11/6/2025 | 24.89 USD |
| 11/5/2025 | 24.61 USD |
| 11/4/2025 | 24.34 USD |
| 11/3/2025 | 24.74 USD |
| 10/31/2025 | 24.70 USD |
| 10/30/2025 | 24.33 USD |
| 10/29/2025 | 24.31 USD |
| 10/28/2025 | 24.55 USD |
| 10/27/2025 | 24.76 USD |
| 10/24/2025 | 24.80 USD |
| 10/23/2025 | 24.71 USD |
| 10/22/2025 | 24.72 USD |
| 10/21/2025 | 24.84 USD |
| 10/20/2025 | 24.69 USD |
| 10/17/2025 | 24.55 USD |
| 10/16/2025 | 24.25 USD |
| 10/15/2025 | 24.43 USD |
| 10/14/2025 | 24.59 USD |
| 10/13/2025 | 24.78 USD |
| 10/10/2025 | 24.64 USD |
| 10/9/2025 | 25.26 USD |
| 10/8/2025 | 25.70 USD |
| 10/7/2025 | 26.28 USD |
| 10/6/2025 | 26.46 USD |
| 10/3/2025 | 27.34 USD |
| 10/2/2025 | 27.09 USD |
| 10/1/2025 | 27.11 USD |
| 9/30/2025 | 25.48 USD |
| 9/29/2025 | 25.48 USD |
| 9/28/2025 | 23.85 USD |
| 9/25/2025 | 23.76 USD |
| 9/24/2025 | 23.60 USD |
| 9/23/2025 | 24.13 USD |
| 9/22/2025 | 24.15 USD |
| 9/19/2025 | 24.05 USD |
| 9/18/2025 | 24.18 USD |
| 9/17/2025 | 24.10 USD |
| 9/16/2025 | 23.93 USD |
| 9/15/2025 | 23.98 USD |
| 9/12/2025 | 23.96 USD |
| 9/11/2025 | 24.86 USD |
| 9/10/2025 | 24.57 USD |
| 9/9/2025 | 24.70 USD |
| 9/8/2025 | 24.57 USD |
| 9/5/2025 | 24.87 USD |
| 9/4/2025 | 24.51 USD |
| 9/3/2025 | 24.77 USD |
| 9/2/2025 | 24.97 USD |
| 8/29/2025 | 24.78 USD |
| 8/28/2025 | 24.64 USD |
| 8/27/2025 | 25.09 USD |
| 8/26/2025 | 24.96 USD |
| 8/25/2025 | 25.20 USD |
| 8/22/2025 | 25.87 USD |
| 8/21/2025 | 25.74 USD |
| 8/20/2025 | 25.37 USD |
| 8/19/2025 | 25.28 USD |
| 8/18/2025 | 25.06 USD |
Pfizer Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Pfizer Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESB |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.85 | 52.82 | 52.55 | 53.65 | 41.17 | 41.65 | 81.29 | 100.33 | 59.55 | 63.63 | 62.58 | 62.23 | 59.85 | 54.75 | 53.42 | 53.82 |
| -1.52 | 8.13 | -0.53 | 2.10 | -23.25 | 1.16 | 95.16 | 23.43 | -40.64 | 6.84 | -1.65 | -0.55 | -3.83 | -8.53 | -2.42 | 0.75 |
| 73.07 | 69.80 | 69.97 | 70.16 | 69.34 | 71.74 | 57.67 | 61.89 | 50.95 | 65.77 | 70.33 | 70.33 | 70.33 | 70.33 | 70.33 | 70.33 |
| 35.69 | 36.87 | 36.77 | 37.64 | 28.55 | 29.88 | 46.88 | 62.09 | 30.34 | 41.85 | 44.01 | 43.77 | 42.10 | 38.50 | 37.57 | 37.85 |
| 13.30 | 9.54 | 14.39 | 15.29 | 7.51 | 9.09 | 22.05 | 37.55 | 5.29 | 10.57 | 10.19 | 13.17 | 12.64 | 11.67 | 11.39 | 11.47 |
| 27.22 | 18.05 | 27.39 | 28.50 | 18.24 | 21.81 | 27.12 | 37.43 | 8.89 | 16.61 | 16.29 | 21.16 | 21.12 | 21.32 | 21.32 | 21.31 |
| 6.97 | 7.22 | 21.31 | 11.15 | 16.27 | 9.16 | 22.15 | 31.37 | 2.13 | 8.02 | 7.77 | 16.98 | 16.52 | 13.91 | 13.14 | 13.41 |
| -23.28 | 3.57 | 195.29 | -47.65 | 45.91 | -43.72 | 141.81 | 41.62 | -93.20 | 276.00 | -3.12 | 118.49 | -2.71 | -15.77 | -5.53 | 2.04 |
| 1.12 | 1.50 | 1.58 | 1.36 | 1.44 | 1.52 | 1.56 | 1.60 | 2.05 | 1.68 | 1.72 | 1.72 | 1.76 | 1.80 | – | – |
| 7.69 | 33.93 | 5.33 | -13.92 | 5.88 | 5.56 | 2.63 | 2.56 | 28.12 | -18.05 | 2.38 | – | 2.33 | 2.27 | – | – |
| 6.17 | 6.14 | 6.06 | 5.79 | 5.63 | 5.66 | 5.77 | 5.74 | 5.65 | 5.70 | 5.69 | 5.69 | 5.69 | 5.69 | 5.69 | 5.69 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Pfizer generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Pfizer retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Pfizer's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Pfizer has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Pfizer's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Pfizer stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Pfizer Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Pfizer business model & stock analysis
Pfizer SWOT Analysis
Strengths
Pfizer Inc. possesses several strengths that contribute to its success in the pharmaceutical industry. One of its key strengths is its extensive portfolio of innovative drugs and treatments. The company invests heavily in research and development, allowing it to continuously develop and introduce new products to the market. Pfizer's strong brand reputation and global presence also contribute to its competitive advantage.
Another major strength is Pfizer's robust financial position. The company has a solid revenue stream, driven by the high demand for its products, and maintains a strong profitability margin. This financial stability enables Pfizer to invest in strategic acquisitions and partnerships, further strengthening its position in the industry.
Weaknesses
Despite its strengths, Pfizer Inc. also faces certain weaknesses that need to be addressed. One weakness is its heavy reliance on a few key products for a significant portion of its revenue. This exposes the company to risks associated with patent expirations and competition from generic drug manufacturers. Pfizer needs to focus on diversifying its product portfolio to reduce this dependency.
Another weakness is the potential negative impact of regulatory changes and legal issues on Pfizer's operations. The pharmaceutical industry is subject to strict regulations, and any change or legal challenge can disrupt Pfizer's business activities and profitability. Close monitoring of regulatory developments and proactive compliance strategies are essential to mitigate these risks.
Opportunities
Pfizer Inc. has several opportunities to capitalize on in the constantly evolving pharmaceutical market. One significant opportunity lies in the growing demand for personalized medicine and targeted therapies. Pfizer can leverage its expertise and research capabilities to develop innovative treatments that cater to specific patient populations, creating a competitive edge in the market.
Furthermore, the increasing focus on healthcare and medical advancements presents an opportunity for Pfizer to expand into emerging markets with high growth potential. By targeting underserved regions, the company can tap into new customer segments and drive revenue growth. Strategic collaborations with local healthcare providers and governments can further enhance Pfizer's market penetration in these regions.
Threats
Like any other company in the pharmaceutical industry, Pfizer Inc. faces several threats that could impact its business. One major threat is the intense competition within the market. The industry is highly competitive, with numerous pharmaceutical companies striving to develop breakthrough drugs and gain market share. Pfizer needs to continuously innovate and stay ahead to maintain its competitive position.
Additionally, the potential risk of counterfeit drugs poses a threat to Pfizer's reputation and revenue. Counterfeit drugs can harm patients and erode trust in the company's products. Pfizer should strengthen its supply chain security and invest in advanced technologies to detect and combat counterfeit drugs effectively.
Moreover, changes in healthcare policies and pricing regulations can significantly impact Pfizer's profitability. Government policies aimed at cost containment or price controls can restrict the company's ability to set prices for its products, thereby affecting its financial performance. Continuous monitoring of these policies and proactive engagement with policymakers is crucial to minimize potential risks.
Pfizer Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Pfizer Segments
Pfizer Revenue by Segment (1/14)
Max
Details
Pfizer Revenue by Segment (2/14)
3 Years
5 Years
Max
Details
Pfizer Revenue by Segment (3/14)
3 Years
5 Years
Max
Details
Pfizer Revenue by Segment (4/14)
3 Years
5 Years
Max
Details
Pfizer Revenue by Segment (5/14)
3 Years
5 Years
Max
Details
Pfizer Revenue by Segment (6/14)
3 Years
5 Years
Max
Details
Pfizer Revenue by Segment (7/14)
3 Years
Max
Details
Pfizer Revenue by Segment (8/14)
3 Years
5 Years
10 Years
Max
Details
Pfizer Revenue by Segment (9/14)
3 Years
5 Years
Max
Details
Pfizer Revenue by Segment (10/14)
3 Years
5 Years
Max
Details
Pfizer Revenue by Segment (11/14)
3 Years
5 Years
Max
Details
Pfizer Revenue by Segment (12/14)
3 Years
Max
Details
Pfizer Revenue by Segment (13/14)
3 Years
5 Years
10 Years
Max
Details
Pfizer Revenue by Segment (14/14)
3 Years
5 Years
Max
Details
Pfizer Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Pfizer Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Pfizer historical P/E ratio, EBIT multiple, and P/S ratio
Pfizer annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Pfizer shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Pfizer stock splits
Pfizer Dividend History
37 years of dividend payments
Pfizer dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Pfizer dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Pfizer forecasts and price targets in August 2026
Analyst Price Targets 2026Pfizer Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 7/13/2026 | Maintained | Buy | 30 | |
| 7/13/2026 | Maintained | Outperform | – | |
| 7/10/2026 | Maintained | Neutral | 70 | |
| 7/8/2026 | Maintained | Neutral | 80 | |
| 7/6/2026 | Downgrade | BuyHold | – | |
| 7/6/2026 | Maintained | Neutral | 44 | |
| 6/10/2026 | Upgrade | UnderperformSector Perform | 52 | |
| 4/29/2026 | Maintained | Neutral | 48 | |
| 4/20/2026 | Maintained | Underperform | 52 | |
| 4/13/2026 | Maintained | Neutral | 51 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Pfizer Earnings Calls
Pfizer Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/4/2026 | 0.69USD | - | 14.57 BUSD | - | 2026 Q2 |
| 5/5/2026 | 0.71USD | - | 13.94 BUSD | - | 2026 Q1 |
| 2/3/2026 | 0.58USD | - | 17.13 BUSD | - | 2025 Q4 |
| 4/30/2024 | 0.86USD | - | 15.60 BUSD | - | 2024 Q1 |
| 1/29/2024 | -0.17USD | - | 14.55 BUSD | - | 2023 Q4 |
| 7/26/2023 | 1.03USD | - | 17.08 BUSD | - | 2023 Q2 |
| 5/1/2023 | 1.25USD | - | 18.85 BUSD | - | 2023 Q1 |
| 2/6/2023 | 1.04USD | - | 24.79 BUSD | - | 2022 Q4 |
| 11/1/2022 | 1.40USD | - | 21.36 BUSD | - | 2022 Q3 |
| 7/28/2022 | 1.80USD | - | 26.12 BUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Pfizer stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Pfizer shareholder structure
| % | Name |
|---|---|
8.72147% | |
6.46648% | |
5.27901% | |
2.33786% | |
2.04332% | |
1.83729% |
Pfizer Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
23.10% | SEC ↗ | |
23.10% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
9.00% | SEC ↗ | |
8.29% | SEC ↗ | |
7.30% | SEC ↗ | |
7.02% | SEC ↗ |
Pfizer Executives and Management Board
22 members · avg. age 61 · 27 % women
Dr. Albert Bourla (63)
Chairman of the Board, Chief Executive Officer · since 2014
24.65 M USD
Management
Mr. Aamir Malik (49)
Executive Vice President, Chief US Commercial Officer
Mr. David Denton (59)
Executive Vice President, Chief Financial Officer
Dr. Chris Boshoff (61)
Chief Scientific Officer, President - Research & Development
Mr. Douglas Lankler (59)
Executive Vice President, Chief Legal Officer
Ms. Payal Sahni (50)
Executive Vice President, Chief People Experience Officer
Ms. Lidia Fonseca (56)
Executive Vice President, Chief Digital and Technology Officer
Board of Directors
Mr. Shantanu Narayen (61)
Lead Independent Director
Ms. Suzanne Johnson (67)
Independent Director
Mr. Joseph Echevarria (68)
Independent Director
Dr. Scott Gottlieb (52)
Independent Director
Mr. James Smith (65)
Independent Director
Dr. Dan Littman (72)
Independent Director
Pfizer Supply Chain
Pfizer Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.28 | 0.60 | 0.81 | ||
| 2 | -0.22 | 0.40 | 0.78 | ||
| 3 | 0.46 | 0.13 | 0.73 | ||
| 4 | 0.39 | 0.08 | 0.73 | ||
| 5 | 0.25 | 0.57 | 0.63 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | — | — | — | ||
| 2 | 0.08 | -0.54 | — | ||
| 3 | -0.07 | 0.57 | — | ||
| 4 | 0.07 | -0.75 | — | ||
| 5 | 0.58 | -0.73 | — |
Frequently asked questions about Pfizer
Pfizer Inc's business model is focused on pharmaceutical research, development, manufacturing, and sales. The company operates in various therapeutic areas, including but not limited to oncology, cardiovascular, immunology, and neurology. Pfizer's mission is to discover and develop innovative medicines that enhance the health and well-being of people worldwide. With a diverse portfolio of prescription medicines, vaccines, and consumer healthcare products, Pfizer strives to improve patient outcomes and provide effective healthcare solutions. Through strategic partnerships and collaborations, Pfizer continues to invest in research and development to address unmet medical needs and drive sustainable growth in the pharmaceutical industry.
Pfizer Inc is primarily active in the pharmaceutical industry.
The main competitors of Pfizer Inc in the market include pharmaceutical companies such as Johnson & Johnson, Novartis AG, Merck & Co., Inc., and GlaxoSmithKline plc.
Pfizer Inc. is a renowned pharmaceutical giant with a rich history and influential background. Established in 1849, Pfizer has evolved into one of the largest global pharmaceutical companies. Headquartered in New York City, Pfizer has played a pivotal role in the healthcare industry's advancement. The company is committed to developing innovative medicines and vaccines that improve and save lives worldwide. With its vast expertise, extensive research and development efforts, and strategic collaborations, Pfizer has introduced groundbreaking treatments for various diseases. As a leader in the pharmaceutical sector, Pfizer continues to prioritize delivering transformative healthcare solutions to address the evolving needs of patients and healthcare professionals.
Pfizer Inc has achieved significant milestones throughout its history. Founded in 1849, the company has become one of the world's leading pharmaceutical corporations. Notably, Pfizer developed and marketed groundbreaking drugs that have revolutionized medical treatments. In 1998, the company gained immense recognition with the introduction of Viagra, a medication for erectile dysfunction. Pfizer's research and innovation also led to the development of Lipitor, a cholesterol-lowering drug that became the best-selling prescription medicine worldwide. Furthermore, Pfizer remains dedicated to advancing healthcare by continuously expanding its product portfolio and pursuing collaborations to address unmet medical needs. With its rich history and commitment to innovation, Pfizer Inc continues to make significant contributions to the healthcare industry.
Pfizer Inc is primarily present in various countries and regions across the globe. The company has a widespread presence with operations in multiple key markets. Pfizer's global presence includes major countries such as the United States, United Kingdom, Germany, Japan, China, India, Brazil, and many more. With a diverse international footprint, Pfizer Inc continues to serve patients and healthcare professionals worldwide by delivering innovative healthcare solutions and medications.
Pfizer Inc, a renowned pharmaceutical company, represents values of integrity, excellence, and patient-centricity. With a strong corporate philosophy, Pfizer aims to improve the health and well-being of individuals worldwide through innovative medicines and therapies. Committed to scientific advancement, Pfizer provides quality healthcare solutions while upholding ethical practices. Through extensive research and development, they strive to discover and deliver life-saving and life-enhancing treatments. As a global leader in the healthcare industry, Pfizer's dedication to patient care, scientific ingenuity, and ethical principles are fundamental to their corporate philosophy and drive their mission to revolutionize healthcare for a better tomorrow.
Analysts currently set an average price target of 29.54 USD for the Pfizer stock (median: 28.56 USD), implying +10.2 % versus the latest price. The consensus is based on 33 analyst ratings.
33 analysts currently rate the Pfizer stock: 15 recommend buying, 17 holding and 1 selling. For 2026, analysts expect Pfizer to generate revenue of 62.23 B USD and earnings per share of 2.99 USD.
Converted at the current exchange rate, the Pfizer share trades at 23.15 EUR (26.79 USD).
The Pfizer share (PFE) is listed on 13 stock exchanges, including: NYSE (PFE), NASDAQ (PFE), XETRA (PFE.DE), Frankfurt (PFE.F), München (PFE.MU), Stuttgart (PFE.SG), Düsseldorf (PFE.DU), Berlin (PFE.BE).
Pfizer Inc is a multinational pharmaceutical company headquartered in New York City. The company operates in the research, development, production, and distribution of drugs. Pfizer is one of the largest pharmaceutical companies in the world. In this article, we will describe the business model of Pfizer Inc. Divisions Pfizer has divided its business operations into three main divisions: Biopharmaceuticals, Beyond the Baby Cure, and Contract Manufacturing. Biopharmaceuticals The Biopharmaceuticals division focuses on the research and development of drugs. The goal is to develop new drugs and therapies that meet the needs of patients. Research and development are focused on various areas such as oncology, cardiovascular, immunological, and neuroscience disorders. Pfizer has a strong pipeline with numerous drugs in late-stage clinical development. An example is the drug Tofacitinib, which is used to treat rheumatoid arthritis. In 2020, Pfizer generated revenue of $51.8 billion in this division. Beyond the Baby Cure The Beyond the Baby Cure division refers to products that are not drug-based. This includes products like vitamin-rich dietary supplements, pain relievers, condoms, and personal care products. Pfizer acquired Wyeth in 2006, a company active in this segment. This allowed Pfizer to expand its product portfolio. In 2020, Pfizer generated revenue of $2.5 billion in this segment. Contract Manufacturing Pfizer's Contract Manufacturing division refers to the production of drugs for other companies. The company offers services for the entire value chain, from drug manufacturing to logistics. In 2020, Pfizer generated revenue of $2.2 billion in this division. Products Pfizer offers a wide range of products covering various areas. Here are some of Pfizer's key products: - Viagra, a medication for the treatment of erectile dysfunction - Lyrica, a medication for the treatment of neuropathic pain - Prevnar, a vaccine for the prevention of pneumococcal infections - Xeljanz, a medication for the treatment of rheumatoid arthritis - Lipitor, a medication for lowering cholesterol levels Conclusion Pfizer is a leading pharmaceutical company with a broad portfolio of products and services. The company specializes in three main divisions: Biopharmaceuticals, Beyond the Baby Cure, and Contract Manufacturing. With a strong commitment to research and development and an impressive pipeline, Pfizer has a strong position in the industry.
The expected revenue of Pfizer is 62.23 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Pfizer is 16.98 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Pfizer is currently 8.97. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pfizer stock.
The price-to-sales ratio (P/S) of Pfizer is currently 2.45. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pfizer stock.
The Eulerpool Quality Score for Pfizer is 2/10.
The ISIN of Pfizer is US7170811035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Pfizer is 852009. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Pfizer is PFE. The ticker symbol is used to trade Pfizer shares on the stock exchange.
Over the past 12 months, Pfizer paid a dividend of 1.72 USD . This corresponds to a dividend yield of about 6.42 %. For the coming 12 months, Pfizer is expected to pay a dividend of 1.76 USD.
The current dividend yield of Pfizer is 6.42 %.
Pfizer pays a dividend, distributed in the months of , , , .
Pfizer paid dividends every year for the past 36 years.
For the upcoming 12 months, dividends amounting to 1.76 USD are expected. This corresponds to a dividend yield of 6.57 %.
Pfizer is assigned to the 'Health' sector.
In the year 2025, Pfizer distributed 1.69 USD as dividends.
The dividends of Pfizer are distributed in USD.
Pfizer stock
Pfizer Peer Group
Pfizer Ticker
Pfizer FIGI
All fundamentals and in-depth analysis of Pfizer
Our stock analysis for Pfizer stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pfizer. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.